For decades, systemic therapy selection in atopic dermatitis has largely relied on clinical judgment and trial-and-error. The prospective IDENTITY study by Silverberg and colleagues challenges that paradigm.

In this episode of Skin in the Game, we unpack the landmark JAAD study evaluating a 487-gene expression profile designed to identify the dominant inflammatory pathway in individual patients and guide systemic treatment selection. We discuss how the test works, review the study design and key efficacy outcomes, explore its strengths and limitations, and debate whether molecular phenotyping is ready for everyday clinical practice.

Most importantly, we discuss what this means for real-world dermatologists: Which patients might benefit? How could this change treatment sequencing? And are we entering the era of precision medicine for atopic dermatitis?

Join us as we separate the hype from the evidence and discuss whether IDENTITY represents the future of personalized AD care.

Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.

Hosted by:
• Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV
• Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VA

We read the research so you don’t have to.

For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/

Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.